However, glutaminase inhibition in specific tumor contexts, such as in STK11/LKB1-deficient lung cancer, may impair CD8+ T cell activation by limiting the expansion of T cell receptor clonotypes, a critical component for robust antitumor immunity [94]. Here, CD8A is linked to neoplasm.